Showing 821-830 of 1478 results for "".
- Aesthetics Biomedical's Vivace Ultra Wins FDA Clearancehttps://practicaldermatology.com/news/aesthetics-biomedicals-vivace-ultra/2461390/The FDA has given the nod to Aesthetics Biomedical Inc.’s Vivace Ultra for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis. An innovative reimagination and technical upgrade of the legacy Vivace Microneedle RF device, the Vivace Ultra comb
- Galderma's Alastin Rolls Out Pigment-Reducing A-LUMINATE BRIGHTENING SERUMhttps://practicaldermatology.com/news/galdermas-alastin-rolls-out-pigment-reducing-a-luminate-brightening-serum/2461386/Galderma’s ALASTIN Skincare is rolling out A-LUMINATE BRIGHTENING SERUM to help reduce the appearance of surface pigmentation without any harsh, irritating ingredients. A-LUMINATE BRIGHTENING SERUM contains a multifaceted blend of peptides, antioxidants, and targeted in
- Castle Bioscience’s DecisionDx-SCC Test Boosts Mohs Surgeons' Confidencehttps://practicaldermatology.com/news/castle-biosciences-decisiondx-scc-test-boosts-mohs-surgeons-confidence/2461382/Castle Bioscience’s DecisionDx-SCC test results can assist Mohs surgeons in making risk-aligned management plans and increase confidence in their treatment decisions, according to data presented at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting. DecisionD
- Study: Galderma's RelabotulinumtoxinA Earns High Marks from Patientshttps://practicaldermatology.com/news/study-galdermas-relabotulinumtoxina-earns-high-marks-from-patients/2461377/Galderma's investigational ready-to-use liquid botulinum toxin RelabotulinumtoxinA scored high patient satisfaction and psychological well-being ratings for the treatment of glabellar lines and lateral canthal lines in addition to previously reported safety and efficacy, according to pre
- National Physician Assistant Week Celebrates Work of PAshttps://practicaldermatology.com/news/national-physician-assistant-week-celebrates-work-of-pas/2461373/The American Academy of Physician Associates (AAPA) is celebrating National Physician Assistant Week October 6-12 to recognize the PA profession and its contributions to the nation’s health. This PA Week, the AAPA wants to spread the word: PAs Go Beyond! Do you know a PA who goes beyond? Th
- Johnson & Johnson Announces Kenvue as the Name for New Consumer Health Companyhttps://practicaldermatology.com/news/johnson-johnson-announces-kenvue-as-the-name-for-new-consumer-health-company/2461363/Johnson & Johnson’s planned new consumer health company will be named...Kenvue. Kenvue (pronounced ken·view), is inspired by two powerful ideas: “ken” – meaning knowledge, an English word primarily used in Scotland, and “vue,” ref
- FDA Clears CellFX System for the Treatment of SHhttps://practicaldermatology.com/news/fda-clears-cellfx-system-for-the-treatment-of-sh/2461358/The U.S. Food and Drug Administration (FDA) granted Pulse Bioscience’s CellFX System (FDA) 510(k)marketing clearance for the treatment of sebaceous hyperplasia in patients with Fitzpatrick skin types I-II. This specific indication clearance enhances the CellFX
- EMA Accepts Marketing Authorization Applications for UCB's Bimekizumab in Psoriatic Arthritis and Axial Spondyloarthritishttps://practicaldermatology.com/news/ema-accepts-marketing-authorization-applications-for-ucbs-bimekizumab-in-psoriatic-arthritis-and-axial-spondyloarthritis/2461354/The European Medicines Agency (EMA) has accepted for regulatory review the two marketing authorization applications for UCB's bimekizumab for the treatment of adult patients with active psoriatic arthritis (PsA), and adult patients with active axial spondyloarthritis (axSpA). &ldquo
- A New Look for Merz Aestheticshttps://practicaldermatology.com/news/a-new-look-for-merz-aesthetics/2461352/Merz Aesthetics has launched a new corporate visual identity to underscore the company's commitment to putting the definition of beauty back into the hands of the individual through a vibrant and distinct color palette along with strong and joyful photography. The new visual identit
- CHMP Recommends Adtralza (tralokinumab) for the Treatment of Adolescents With Moderate-to-Severe ADhttps://practicaldermatology.com/news/chmp-recommends-adtralza-tralokinumab-for-the-treatment-of-adolescents-with-moderate-to-severe-ad/2461351/The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) is recommending extending the approval of LEO Pharma’s Adtralza (tralokinumab) to include adolescents aged 12 to 17 with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic